Neutral
Our verdict — Wolfe Research ranks #16 of 64 in our leaderboard: 59.6% hit rate across all stocks, 15.7% average gain per call, +9 pts vs its sector.
Moderna (MRNA) price target — analyst by analyst
Moderna · Health Care · ref. ETF XLV · price $142.77
By Rédaction JPI Invest · updated
In short — 14 price targets published on Moderna over 90 days: 2 bullish, 3 bearish (14% positive), median target $67. The highest-ranked firm to weigh in is William Blair (rank 7, 76.5% hit rate). For each call below we show the firm's real track record — not just its opinion.
The last 14 analyst calls on MRNA
Newest first. The "verdict" is our read on the firm, based on its past calls replayed against actual prices.
Neutral
Our verdict — Barclays ranks #52 of 64 in our leaderboard: 33.3% hit rate on Moderna (6 scored calls on this stock), 10.6% average gain per call, +2 pts vs its sector.
Bearish
Our verdict — JP Morgan ranks #37 of 64 in our leaderboard: 60% hit rate on Moderna (5 scored calls on this stock), 15.8% average gain per call, +4 pts vs its sector.
Neutral
Our verdict — Goldman Sachs ranks #25 of 64 in our leaderboard: 16.7% hit rate on Moderna (6 scored calls on this stock), 16.6% average gain per call, +5 pts vs its sector.
Neutral
Our verdict — UBS ranks #27 of 64 in our leaderboard: 50% hit rate on Moderna (6 scored calls on this stock), 17% average gain per call, +5 pts vs its sector.
Neutral
Our verdict — Morgan Stanley ranks #49 of 64 in our leaderboard: 100% hit rate on Moderna (4 scored calls on this stock), 12.2% average gain per call, +3 pts vs its sector.
Bullish
Our verdict — William Blair ranks #7 of 64 in our leaderboard: 76.5% hit rate across all stocks, 28.6% average gain per call, +13 pts vs its sector.
Neutral
Our verdict — Citigroup ranks #24 of 64 in our leaderboard: 65.5% hit rate across all stocks, 20.1% average gain per call, +5 pts vs its sector.
Neutral
Our verdict — Goldman Sachs ranks #25 of 64 in our leaderboard: 16.7% hit rate on Moderna (6 scored calls on this stock), 16.6% average gain per call, +5 pts vs its sector.
Neutral
Our verdict — Morgan Stanley ranks #49 of 64 in our leaderboard: 100% hit rate on Moderna (4 scored calls on this stock), 12.2% average gain per call, +3 pts vs its sector.
Neutral
Our verdict — RBC Capital ranks #62 of 64 in our leaderboard: 0% hit rate on Moderna (9 scored calls on this stock), 9% average gain per call, -2 pts vs its sector.
Bearish
Our verdict — B of A Securities ranks #31 of 64 in our leaderboard: 25% hit rate on Moderna (4 scored calls on this stock), 17.5% average gain per call, +5 pts vs its sector.
Bullish
Our verdict — Piper Sandler ranks #26 of 64 in our leaderboard: 20% hit rate on Moderna (10 scored calls on this stock), 19.9% average gain per call, +5 pts vs its sector.
Bearish
Our verdict — B of A Securities ranks #31 of 64 in our leaderboard: 25% hit rate on Moderna (4 scored calls on this stock), 17.5% average gain per call, +5 pts vs its sector.
⚠️ Price targets as published by the firms, timestamped at their publication date. The upside shown is vs the price on the day of the call, not today's price. Informational data, not investment advice.
Frequently asked questions
What are analysts saying about MRNA right now?
Over the last 90 days, 14 price targets were published on Moderna: 2 bullish and 3 bearish (14% positive). The median target is $67. The latest call is from August 25, 2026.
Should you trust these price targets?
Not blindly — that's the point of this page: next to each call we show the firm's real track record — its rank among 64 tracked firms, its hit rate and its average gain per call. An ambitious target from a firm that is wrong 6 times out of 10 is not worth the same as one from a consistent firm.
Which firm covering MRNA is the most reliable?
Among the firms that published on Moderna in the last 90 days, our highest-ranked is William Blair (rank 7 of 64, 76.5% hit rate, 28.6% average gain per call).
Where does this data come from?
From analyst price targets, timestamped at publication then replayed against the actual price. Firm rankings come from our analyst leaderboard. Updated daily.
💬 A question about Moderna? The JPI assistant answers using our backtest data.